Titre du document / Document title

Lanzoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy

Auteur(s) / Author(s)

Lanzoprazole Maintenance Study Group, ETATS-UNIS
SONTAG S. J. ; KOGUT D. G. ; FLEISCHMANN R. ; CAMPBELL D. R. ; RICHTER J. ; HABER M. ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

Veterans Affairs Hospital, Hines, Illinois, ETATS-UNIS
Piedmont Gastroenterology, Statesville, North Carolina, ETATS-UNIS
Metroplex Clinical Research Center, Dallas, Texas, ETATS-UNIS
Veterans Affairs Medical Center, Kansas City, Missouri, ETATS-UNIS
Cleveland Clinic Foundation, Cleveland, Ohio, ETATS-UNIS
Medical College of PA, Philadelphia, Pennsylvania, ETATS-UNIS
TAP Holdings Inc., Deerfield, Illinois, ETATS-UNIS

Résumé / Abstract

Objective : This randomized, double-blind study was designed to determine whether the proton pump inhibitor lansoprazole could prevent relapse among patients with healed erosive reflux esophagitis that had been resistant to healing with at least 3 months of H₂-receptor antagonist therapy. Results : By the end of the year, 13% of placebo patients remained healed compared with 67% of lansoprazole 15 mg and 55% of lansoprazole 30 mg patients (p < 0.001 for time to first relapse). All placebo patients were symptomatic by the end of the study whereas only one-third of the lansoprazole patients was symptomatic at the end of the 12-month study period. The two lansoprazole doses were comparably effective in maintaining healing and in symptom control and were well tolerated. Fasting serum gastrin values increased significantly to about 1.5-2 times the baseline values over the first 2 months of lansoprazole treatment ; no further increase was noted. Conclusion : Erosive relapse can be prevented in most patients for up to 1 yr with lansoprazole 15 mg or 30 mg once daily.

Revue / Journal Title

The American journal of gastroenterology   ISSN 0002-9270 

Source / Source

Congrès
Annual Scientific Meeting American College of Gastroenterology N^o61, Seattle, Washington , ETATS-UNIS (21/10/1996)
1996, vol. 91, n^o 9, pp. 1881-2047 (19 ref.), pp. 1758-1765

Langue / Language

Anglais

Editeur / Publisher

Blackwell Publishing, Oxford, ROYAUME-UNI  (1954) (Revue)

Mots-clés anglais / English Keywords

Gastroesophageal reflux ; Complication ; Esophagitis ; Negative therapeutic reaction ; Antagonist ; H2 receptor ; Biological effect ; Antisecretory agent ; Recurrence ; Erosion ; Treatment efficiency ; Human ; Digestive diseases ; Esophageal disease ; Chemotherapy ;

Mots-clés français / French Keywords

Reflux gastrooesophagien ; Complication ; Oesophagite ; Résistance traitement ; Antagoniste ; Récepteur histaminergique H2 ; Effet biologique ; Antisécrétoire ; Lansoprazole ; Récurrence ; Erosion ; Efficacité traitement ; Homme ; Appareil digestif pathologie ; Oesophage pathologie ; Chimiothérapie ;

Mots-clés espagnols / Spanish Keywords

Reflujo gastroesofágico ; Complicación ; Esofagitis ; Resistencia al tratamiento terapeútico ; Antagonista ; Receptor histaminérgico H2 ; Efecto biológico ; Antisecretorio ; Recurrencia ; Erosión ; Eficacia tratamiento ; Hombre ; Aparato digestivo patología ; Esófago patología ; Quimioterapia ;

Localisation / Location

INIST-CNRS, Cote INIST : 11062, 35400006425194.0140